ANABV — AnaptysBio Share News
0.000.00%
Last trade - 00:00- $1.94bn
- $1.91bn
- $234.60m
Brief: AnaptysBio's Complaint Against Tesaro For Breaching Agreement Was Publicly Filed On Nov 26 - SEC Filing
U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, Alphabet
AnaptysBio shares tumble after legal fight with GSK over cancer drug license (updated)
U.S. STOCKS ON THE MOVE-Intuit, IES Holding, Workday
AnaptysBio tumbles after latest legal battle over cancer drug
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Esperion rises as partner launches cholesterol drug in Japan
U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare
U.S. STOCKS ON THE MOVE-Eli Lilly, Fossil, Papa John's
AnaptysBio falls after ulcerative colitis drug fails in mid-stage trial
AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales
Brief: AnaptysBio Q3 Net Income USD 15.113 Million
Brief: Anaptys Announces New Positive Phase 2B Trial Results For Rosnilimab In Rheumatoid Arthritis
U.S. RESEARCH ROUNDUP- Applovin, Caterpillar, ESAB
U.S. STOCKS ON THE MOVE-Nike, Occidental Petroleum, Veeco Instruments
U.S. STOCKS ON THE MOVE-Nike, Occidental Petroleum, Carvana
AnaptysBio climbs after Leernik raises PT on investor-friendly spinoff plans
Brief: Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026
AnaptysBio Q2 collaboration revenue doubles